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Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease with an unknown 
cause, high prevalence, and no effective therapy. Alterations in gut microbiota com-
position and function have been found in PD, which could influence the gut-brain 
axis. Several mechanisms have been proposed and are investigated to explain the link 
between gut microbiota and PD. In model systems and in individual case reports, 
modulation of gut microbiota has been associated with improvement of PD. A safe 
and effective way of gut microbiota manipulation is fecal microbiota transplant (FMT). 
FMT is used successfully for treatment of recurrent gastrointestinal infections as well 
as other indications. We advocate randomized clinical trials with FMT as a treatment 
option for PD.
Keywords: Parkinson’s disease, gut microbiota, fecal microbiota transplantation, 
clinical trial
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disease which is accompanied by gastroin-
testinal dysfunction in 80% of patients [1]. PD has a high prevalence, affecting almost 2% of 
people over the age of 80 [2] and is currently incurable, although a variety of therapies are 
available to treat the symptoms [3]. In the last decade, the hypothesis has gained support 
that PD starts in the gut and spreads through the sympathetic and parasympathetic nervous 
systems to the substantia nigra and the central nervous system [4, 5]. More recently, it has 
been recognized that these brain-gut axis interactions in PD may be essentially influenced by 
gut microbiota.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
In this opinion paper we want to encourage the design and initiation of clinical trial using 
fecal microbiota transplantation (FMT) as a therapeutic intervention for PD. We first elaborate 
on the evidence for the role of gut microbiota in PD, followed by a short discussion of FMT, 
and conclude with arguments to support the setup of clinical studies.
2. Alterations in gut microbiota composition in PD patients
A causal link between Helicobacter pylori infections and PD has been suggested for a long time 
[6, 7]. Even before the discovery of H. pylori, the connection between PD and gastric ulcers has 
already been reported [8, 9], and it was found that duodenal and gastric ulcers often preceded 
the onset of PD by many (10–20) years. Since then, numerous studies have reported that the 
incidence of small intestinal bacterial overgrowth is higher in PD patients than in healthy 
controls [10–13] that PD patients have higher H. pylori antibody levels [14] and that H. pylori 
infections are more prevalent in PD patients than in control groups [15, 16].
Several recent studies show that PD is also preceded or accompanied by changes in the abun-
dance of other bacterial groups. It thus has been found that PD patients harbor lower con-
centrations of Prevotella bacteria [17–21], and the number of Prevotella bacteria is negatively 
correlated with the severity of PD symptoms [20]. Increased numbers of Enterobacteria are 
found in PD patients [17, 22], and the relative abundance of Enterobacteriaceae is positively 
associated with the severity of postural instability and gait difficulty [20]. In another study, sig-
nificantly altered abundances of the Bifidobacteriaceae, Christensenellaceae, (Tissierellaceae), 
Lachnospiraceae, Lactobacillaceae, Pasteurellaceae, and Verrucomicrobiaceae families were 
found in PD patients [23]. In PD patients, Lactobacillus numbers were found to be higher and 
Clostridium coccoides plus Bacteroides fragilis numbers were lower compared to healthy con-
trols, all contributing to a distinct composition of gut microbiota in PD [23]. Concentrations 
of hydrogen-producing bacteria were also higher in PD patients [24]. It has been suggested 
that cyanobacteria can be a source of neurotoxins that are related to PD [25, 26]. Molecular 
analysis of the gut microbiome has shown that 48 operational taxonomic units (OTU’s) of the 
gastrointestinal microbiota have differential abundancy in PD patients versus healthy con-
trols. Some of these OTUs were significantly related to motor symptoms and depression in PD 
patients. Functional analysis of gut microbiota also shows differences between PD patients 
and controls. Increased urinary indoxyl sulfate, a marker of intestinal dysbiosis, is found in 
PD patients [27].
Besides gut microbiota, microbiota at other ecological niches may also differ. The oral micro-
biota of PD patients and control subjects had differences in beta diversity and abundances of 
individual bacterial taxa [28].
3. Mechanistic link between gut microbiota and PD
Various studies suggest that gut microbiota do not just correlate with PD but that PD 
may actually start within the gut, with gut microbiota as a causative agent. The fact that 
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gastrointestinal dysfunction often precedes motor symptoms by 10–15 years already strongly 
suggests a role for gut microbiota. In addition, epidemiological studies in Sweden show that 
gotomy drastically reduces the risk of developing PD [29, 30], suggesting the nervus vagus 
as vagotomy a route via which PD may travel from the gut to the CNS (see also Figure 1). 
Sampson and co-workers found that fecal microbiota transplants from human PD patients in 
a mouse model of PD enhances physical impairments, compared to microbiota transplants of 
healthy donors [31]; a finding which may indicate that alterations in the human microbiome 
represent a risk factor for PD.
Various mechanisms and mediators have been proposed for the relation between gut micro-
biota and development of PD (Figure 1). PD may be initiated by toxins produced by the 
gut microbiota or because of a failure to produce key essential neuronal dopamine specific 
nutrients or enzymes, which are required by dopamine-producing cells [32]. For example, 
decreased numbers of Prevotella are linked to decreased production of important micronutri-
ents like short chain fatty acids, thiamine and folate [19], whereas gut microbes like Bacillus 
spp. are known to produce dopamine [33]. Cyanobacteria are believed to produce the excito-
toxin β-N-methyl amino-L-alanine (BMAA) which has been found to be increased in the brain 
of PD patients [26].
Since PD is assumed to be characterized by synucleinopathy, another potential mechanism 
may be that alpha-synuclein produced by gut microbiota spreads upwards from the gut along 
vagal nerve fibers [34, 35].
It has also been suggested that gut dysbiosis leads to chronic low-grade inflammation in the 
gut, which may ultimately trigger blood-brain barrier leakage, immune cell activation and 
inflammation, and ultimately neuroinflammation in the CNS [36]. Increased intestinal perme-
ability has been described in PD, resulting in penetration of E. coli in the intestinal mucosa as 
well as oxidative stress and increased enteric α-synuclein levels [37].
A more general explanation which has been suggested is that the composition of the gut 
microbiota changes over the human lifespan, which may play a role in age-related dis-
eases [38].
Figure 1. Potential mechanisms of interaction between gut microbiota and the brain in Parkinson’s disease.
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4. Therapeutic interventions in the microbiome as a treatment option 
for PD
The effect of interventions in the microbiome on PD has been demonstrated in mouse models. 
Administration of the antibiotic minocycline prevents nigrostriatal dopaminergic neurode-
generation in a mouse model of PD [39]. Sampson et al. have reported that antibiotic treat-
ment of gut microbiota ameliorates physical impairment, whereas microbial recolonization, 
or the oral administration of specific microbial metabolites, promotes pathophysiology in a 
mouse model of PD [31].
In addition, a number of recent clinical studies in human patients show that various treatments 
of either gastrointestinal dysfunction or gut microbiota composition have a beneficial effect on 
PD. For example, maintenance laxative usage was associated with apparent stemming of the 
temporal increase in rigidity in PD [40]. PD patients who were treated for Helicobacter pylori 
infections experienced prolonged (2–3 years) improvement of motor symptoms compared to 
a control group [41–43]. Furthermore, H. pylori-positive PD patients have significantly poorer 
clinical scores as compared to H. pylori-negative PD patients [16]. Twelve weeks after treat-
ment of the H. pylori infection, improvements in levodopa onset time and effect duration were 
observed, as well as better scores in motor performance and quality of life measures [16]. A 
single non peer-reviewed case study described a PD patient that became symptom-free after 
receiving a fecal microbiota transplant [44].
Other (non-PD related) effects of gut microbiota composition on the nervous system have also 
been reported. For example, a case report of three MS patients records dramatic improvement 
of neurological functions after fecal microbiota transplantation [45]. Significant improvement 
of myoclonus dystonia symptoms was observed in a female patient after receiving fecal micro-
biota transplantation [46]. Microbiota management via probiotic supplementation significantly 
reduced overall cognitive reactivity to sad mood in healthy participants of a placebo controlled, 
randomized clinical trial [47]. Finally, it has been demonstrated that gut microbiota from 
depressed patients could induce depression-like behavior in microbiota-depleted rats [48].
5. Fecal microbiota transplantation
Given the evidence described above, modification of the gut microbiota could be a valid and 
attractive treatment option for PD. The most powerful way to modify the gut microbiota is 
via a fecal microbiota transplantation (FMT). FMT is a relatively new treatment option for 
gut dysbiosis-related diseases; mainly Clostridium difficile infections, for which it is highly 
successful with cure rates of over 90% [49, 50]. FMT involves transfer of stool (containing both 
microbes and the bioactive molecules they produce) from a healthy donor to a patient (see 
[50] for a review). More recently, the therapy is also offered via orally administered capsules 
containing a screened sample of donor microbiota in freeze-dried form, which makes the 
treatment even safer and less invasive.
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As of December 2017, nine stool banks have been installed worldwide [51]; the most recent 
ones being in Madrid and Hong Kong. One of them, OpenBiome, founded by Harvard and 
MIT microbiologists, also offers treatment via capsules (www.openbiome.org). For the time 
being, the stool banks only offer treatments to patients suffering from recurrent C. difficile 
infections. However, they also cooperate in studies on other diseases. FMT is considered the 
most cost-effective treatment option in the treatment of recurrent C. difficile infections [52].
FMT is a safe treatment, provided it is performed in a clinical setting and with the use of 
screened donor feces. Several clinical studies report mild side effects or no side effects at 
all [49, 53–57]. Even in high-risk groups, FMT was found to be safe: no adverse effects were 
found in cancer patients [58] as well as in solid organ transplant recipients [59]. A review by 
Baxter and Colville [60] on the adverse events associated with FMT concludes that “The vast 
majority of adverse events of FMT appear to be mild, self-limiting and gastrointestinal in 
nature.” As for every new treatment, potential long-term negative effects are unknown.
It is important to note that outside clinical settings, there are risks associated with FMT. There 
is a growing “do it yourself” movement around FMT, where many people are experiment-
ing with FMT as a last resort option for incurable diseases like PD. The Internet is teeming 
with discussion fora on which people exchange the best DIY techniques, which may involve 
kitchen blenders and various pumping devices. In a recent review of information regarding 
FMT on social media, it is concluded that “there is a vast amount of information available 
about FMT through social media that has the potential for causing harm” [61]. Donor screen-
ing does not take place if and when people perform the treatment themselves. This may lead 
to patients being put at risk to infections or perforations as a result of unprofessional treat-
ment. For example, it has been reported that a child developed aspiration pneumonia as a 
result of the entrance of fecal matter in the bronchial system after the parents performed FMT 
without medical supervision [62]. Another case study describes a patient who developed a 
cytomegalovirus infection, after performing home FMT using unscreened donor feces [63]. 
These examples underline the importance of FMT to be provided in a clinical setting under 
controlled conditions.
6. Arguments in favor of an RCT
Given the above considerations, there are strong arguments for initiating a clinical study on 
the effect of FMT on PD patients.
a. FMT could potentially provide a treatment option for a disease that affects millions of peo-
ple worldwide, is currently incurable, and is expected to become more prevalent as a result 
of an aging population. Given the idea that age-related diseases may be related to aging 
of the gut microbiota [38], using material from young donors may be especially beneficial.
b. FMT is considered safe, even in high-risk groups.
c. FMT is inexpensive
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d. Safe, screened donor feces material can easily be obtained via one of the existing stool 
banks. A control group can be treated with autologous feces. Alternatively, OpenBiome 
offers the possibility to assist in designing a setup and provide orally administered 
capsules.
e. The best way to stem the DIY movement and prevent dangerous situations as a result of 
people experimenting with FMT, is to offer a safe and controlled alternative in a hospi-
tal setting or to develop safe protocols for home-administered fecal transplantations in a 
health care setting [49, 56].
So far, only one clinical trial has been initiated (ClinicalTrials.gov Identifier: NCT03026231) 
[64]. However, we argue that more clinical trials are warranted. The argument that the 
mechanism via which microbiota affect PD is still poorly understood [65–67] should not 
block further application of FMT. Aspirin, for example, has been effectively applied for 
centuries before the mechanism was finally elucidated in the 1970s. Likewise, levodopa has 
been used for the treatment of PD for decades before its mechanism was unraveled. It may 
take years before the pathways via which gut microbiota affect the brain are unraveled, 
and meanwhile a potentially promising treatment option remains unexplored. Given the 
relative ease and safety of the treatment and the fact that it is already applied on a routine 
basis to C. difficile patients, including these in high-risk groups like cancer patients or organ 
transplant recipients, we advocate more clinical studies. Moreover, a clinical study on FMT 
in PD could lead to a better understanding of the relation between microbiota and the 
nervous system.
Finally, several authors have already pointed out that FMT is a very promising treatment 
option for PD. As stated by Mulak and Bonaz: “The close relationship between gut dysbio-
sis, intestinal permeability and neurological dysfunction suggests that the gut microbiota 
modification may provide a promising therapeutic option in PD” [68]. Fang also stated that 
“Microbiota-based interventions that play a regulatory role in the gut microflora exhibit ther-
apeutic potential” (for PD) [69]. Finally, Scheperjans in 2016 comments in an opinion article: 
“If this endeavor is successful, we may end up with completely new therapeutic approaches 
that could hopefully turn the ship around toward effective disease modification or even pre-
vention” [70].
It took a long time before FMT was generally accepted as a treatment option for C. difficile 
infections because physicians were skeptical about this “19th century technique” or wary of 
any adverse effects [71]. It is unknown how many people died (or are still dying) unnecessar-
ily from otherwise untreatable C. difficile infections or had their colons removed, while it was 
already known that FMT could cure them. The prognosis has finally changed for the better-
ment for these patients. In 2010, a study on the effect of FMT on recurrent C. difficile infection 
in Amsterdam was prematurely terminated because the data and safety monitoring board of 
the hospital considered it unethical to withhold the treatment from the control group [55]. 
FMT thus is on the way to becoming a standard treatment for recurrent C. difficile infections 
in most developed countries.
Given the fact that FMT is a very promising treatment for PD, is safe, not invasive (especially 
using orally administered capsules) and inexpensive, and people are exposing themselves 
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to risks by performing the treatment themselves without medical supervision, it could be 
argued that not starting a trial on the effect of FMT on PD would be similarly unethical. The 
roadmap is clear, and it now just needs to be taken.
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